LWBP
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
LWBP - overview
Established
2012
Location
Shanghai, Shanghai, China
Primary Industry
Pharmaceuticals
About
Founded in 2012 and based in Shanghai, China, Shanghai Longwood Biopharmaceuticals Co. , Ltd. , trading as LWBP specializes in oncology drug development. In October 2025, LWBP raised Series B funding from new investors Xiamen C&D Group, Wuxi Huading Capital, Qiming Venture Partners, Chuchang Fund and Shanghai STVC Group.
LWBP specializes in developing innovative pharmaceuticals that address unmet clinical needs, with a focus on autoimmune diseases, tumor immunotherapy, and antiviral therapies. Its core product, LW231, is a Class 1 new drug designed for the complete cure of hepatitis B and is currently in Phase Ib/II clinical trials. LWBP engages in medical translation and commercialization through partnerships and licensing agreements, extending its market reach beyond China. Revenue generation is structured through partnerships and licensing agreements with pharmaceutical companies and healthcare providers, facilitating direct procurement of treatments by healthcare institutions.
The company aims to provide competitive and affordable solutions for a broad market segment.
Current Investors
Qiming Venture Partners, Shanghai STVC Group, Xiamen C&D Group
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Biotechnology, Pharmaceutical Research & Development, Pharmaceuticals
Website
http://lwbpsh.com
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.